You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Cost–Utility Analysis of the Newly Recommended Adjuvant Chemotherapy for Resectable Gastric Cancer Patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer
|
|---|---|
| Published in |
PharmacoEconomics, May 2013
|
| DOI | 10.1007/s40273-013-0065-2 |
| Pubmed ID | |
| Authors |
Tan Chongqing, Peng Liubao, Zeng Xiaohui, Li Jianhe, Wan Xiaomin, Chen Gannong, Wang Siying, Ouyang Lihui, Zhao Ziying |
| Abstract |
Postoperative adjuvant chemotherapy with capecitabine and oxaliplatin was first recommended for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Gastric Cancer, but the economic influence of this therapy in China is unknown. |
Mendeley readers
The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ecuador | 2 | 4% |
| United Kingdom | 1 | 2% |
| Unknown | 47 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 24% |
| Student > Ph. D. Student | 9 | 18% |
| Other | 6 | 12% |
| Student > Bachelor | 5 | 10% |
| Student > Master | 4 | 8% |
| Other | 5 | 10% |
| Unknown | 9 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 36% |
| Psychology | 3 | 6% |
| Nursing and Health Professions | 2 | 4% |
| Economics, Econometrics and Finance | 2 | 4% |
| Social Sciences | 2 | 4% |
| Other | 9 | 18% |
| Unknown | 14 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 January 2018.
All research outputs
#7,428,992
of 22,711,242 outputs
Outputs from PharmacoEconomics
#842
of 1,814 outputs
Outputs of similar age
#65,531
of 195,058 outputs
Outputs of similar age from PharmacoEconomics
#13
of 27 outputs
Altmetric has tracked 22,711,242 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,814 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 195,058 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.